PSIL vs XPH

PSILFAdvisorShares Psychedelics ETF

XPHBState Street SPDR S&P Pharmaceuticals ETF

In short

PSIL The ticker is the thesis. PSIL is a compact, global, actively run basket of health care companies working on psychedelic medicine, with a stated goal of long-term capital appreciation in a corner of the market almost no other ETF touches.

XPH Most pharma funds are a mega-cap sandwich. XPH equal-weights instead, so a small-cap drugmaker gets roughly the same say as an industry giant, across about 60 names, for 0.35% a year.

Stated mandate

PSIL The Fund seeks long-term capital appreciation.

XPH The fund seeks to provide exposure to the pharmaceuticals segment of the S&P TMI.

Why people hold it

• PSIL One ticker, the whole theme: a global basket of roughly two dozen health care names tied to psychedelic medicine, instead of hand-picking single clinical-stage stocks.advisorshares.com
• Concentrated on purpose. At around 25 positions, the theme stays front and center rather than getting diluted inside a broad mega-cap pharma index.
• Trading since 2021, so there is multi-year live operating history behind the strategy, not a simulated one.

• XPH Modified equal weighting with quarterly rebalances: the index trims what has run and keeps real room for small and mid-cap drugmakers, not just the household names.ssga.com
• At 0.35%, the cheapest sticker in its pharma peer group and well under the group median of 0.57% (PPH 0.36%, IHE 0.37%, PJP 0.57%, FTXH 0.60%).
• Pure pharma, not a health care grab bag: it draws only from the pharmaceuticals segment of the S&P Total Market Index. No insurers, hospitals or device makers.ssga.com
• Running since 2006 under a single index rulebook, with assets in the mid-size range and about 60 holdings behind it.

Worth knowing

• PSIL Expensive by pharma-ETF standards: 1.84% a year, against 0.36% at PPH and 0.35% at XPH. A niche, actively managed mandate carries a niche price tag.
• Small asset base and light trading volume. Spreads can be wide, so limit orders are the standard way to deal with a fund this thinly traded.
• Within its pharma and therapeutics peer group it sits in the bottom quartile, held back mainly by cost and tradability rather than the theme itself.

• XPH Equal weighting pulls the portfolio down the cap ladder, where trial results and FDA decisions can swing a single stock hard. Expect a bumpier ride than mega-cap pharma.ssga.com
• One industry, one country. Drug pricing rules and patent cliffs hit the whole basket at once.
• Moderately traded rather than a volume monster, so spreads can widen. Limit orders are the usual answer.

Full PSIL profile⁠

Full XPH profile⁠